Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T53585 | ||||
| Target Name | HMG-CoA reductase (HMGCR) | ||||
| Synonyms | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | ||||
| Target Type | Successful | ||||
| Gene Name | HMGCR | ||||
| Biochemical Class | CH-OH donor oxidoreductase | ||||
| UniProt ID | HMDH_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Arteriosclerosis | ||||
| Example drug | MK-0524B | Discontinued in Phase 3 | [1], [2], [3] | ||
| Tissue | Peripheral blood | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.23 Z-score: 0.94 P-value: 1.85E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Familial hypercholesterolemia | ||||
| Example drug | Rosuvastatin | Approved | [2], [3], [4], [5] | ||
| Tissue | Whole blood | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.65 Z-score: 1.53 P-value: 1.01E-05 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Myeloma | ||||
| Example drug | Statins | Phase 1/2 | [6], [2], [3] | ||
| Tissue | Bone marrow | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 1.01 Z-score: 4.34 P-value: 1.48E-06 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target's Expression Profile across Various Tissues of Healthy Individual | |||||
|
|||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023729) | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
| REF 3 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2954). | ||||
| REF 5 | Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95. | ||||
| REF 6 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.